Siemens Healthineers AG Earnings Recaps
Q3 2026
Aug 4, 2026
The stock rose 5.1% driven by notably strong order intake and upbeat growth in key segments, especially Precision Therapy and new strategic value partnerships, which more than offset ongoing challenges in Diagnostics and a lowered revenue outlook.
Key takeaways
- Equipment book-to-bill ratio stood at an impressive 1.27, underpinned by two large value partnerships with leading U.S. health institutions.
- Precision Therapy delivered robust 9% growth, while Imaging growth was softer at 5%, impacted by tough prior year comps and temporary revenue timing shifts.
- Diagnostics segment continued to face structural headwinds, particularly in China, with no improvement yet in the rate of decline.
- The company lowered its fiscal 2026 revenue growth guidance to 3.5%-4.0% (from 4.5%-5.0%), citing continued Diagnostics weakness but raised the EPS guidance due to one-time tariff refunds.
- Innovation momentum remains strong, with advances in photon-counting CTs, DryCool MR technology, radiopharmaceutical capacity expansion, and FDA approval of AI-enabled solutions supporting future growth.
Q1 2026
Feb 5, 2026
Siemens Healthineers reported a solid start to fiscal 2026 with strong performance in Imaging and Precision Therapy, despite facing significant challenges in its Diagnostics segment, particularly in the Chinese market.
Key takeaways
- Imaging and Precision Therapy achieved a robust 6% growth with operational margins expanding, effectively countering headwinds from tariffs and foreign exchange fluctuations.
- Diagnostics experienced a 3% revenue decline, primarily impacted by market shifts in China due to volume-based procurement and reimbursement changes.
- The Atellica portfolio surged by approximately 20%, now constituting 70% of core lab solution sales, with notable growth in the Americas.
- Siemens Healthineers received an investment-grade rating from Moody's as part of its ongoing preparations for deconsolidation from Siemens AG, underscoring strong financial health.
- The Elevating Health Globally strategy is gaining traction with positive feedback from clients, reflecting a commitment to address noncommunicable diseases through innovative healthcare solutions.
Q4 2025
Nov 5, 2025
Siemens Healthineers finished fiscal year 2025 with solid growth, exceeding guidance driven by strong global demand, while maintaining a robust book-to-bill ratio.
Key takeaways
- Q4 revenue growth reached 6.5%, contributing to a full-year growth of 6.8%, led by Imaging and Varian segments.
- Adjusted EPS exclusion of tariffs showed a 10% year-over-year increase, reflecting strong operational performance.
- Proposed dividend increased to EUR 1 alongside improvements in free cash flow, reducing leverage to 2.8x EBITDA.
- Book-to-bill ratio for equipment was at 1.12, indicating a healthy sales pipeline despite stagnant performance in China.
- Diagnostics segment margin improvement continues, although revenue growth is subdued due to market challenges in China.